(EMAILWIRE.COM, July 21, 2018 ) Immunotherapy Drugs Market, by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific)-Global Forecast to 2021

F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (U.S.), and Abbvie, Inc. (U.S.) are the leading players in the global immunotherapy drugs market. The strong position of these companies in the market can primarily be attributed to their global presence and broad product portfolio. Other major players in the market include Amgen Inc. (U.S.), Merck & Co., Inc. (U.S), and GlaxoSmithKline (U.K.).

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/immunotherapy-drug-market.asp

F. Hoffmann-La Roche AG (Switzerland) accounted for the largest share of 19.1% of the global immunotherapy drugs market in 2015. The company focuses on the strategy of expansion and product approvals to maintain its footprint in the immunotherapy drugs market. In accordance with this, the company widened its immuno-oncology portfolio with FDA and European marketing authorization approvals for Gazyvaro and Kadcyla, which are used in the treatment of chronic lymphocytic leukemia and breast cancer, respectively. Similarly, in 2016, the company also received FDA approval for TECENTRIQ and European Commission’s approval for Avastin in combination with Tarceva used for treatment of metastatic non-small cell lung cancer.

Johnson & Johnson (U.S.) was the second-largest player in the global immunotherapy drugs market with a market share of 13.1% in 2015. The company mainly focuses on inorganic strategies such as acquisitions, collaborations and approvals to sustain its position in the immunotherapy drugs market. In November 2016, Janssen Biotech, Inc. a division of J&J (U.S.) entered into clinical trial collaboration with Onyx Pharmaceuticals, Inc., a subsidiary of Amgen (U.S.). Similarly, in November 2015, DARZALEX injection, the first human anti-CD38 monoclonal antibody from Janssen Biotech, Inc. has been approved by US-FDA for intravenous infusion for the treatment of patients with multiple myeloma.

Companies in the immunotherapy drugs market are majorly focusing on drugs approval for strengthening their market share; this strategy accounted for ~43% of the total number of strategic developments undertaken by key players in this market.

More info: https://www.marketsandmarkets.com/Market-Reports/immunotherapy-drug-market-137717755.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
sales@marketsandmarkets.com